BioNTech Financials - Benzinga

BioNTech SE

BNTXNASDAQ

Trade with Public

Trade with Public

$103.20

-0.61-0.59%

Ult. Agg.: Sep 3, 12:54 PM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

BioNTech Financials

BioNTech (BNTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est

BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 billion-$2.209 billion vs $2.500 billion estimate.

Benzinga Newsdesk

PRO
BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M Estimate

BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst consensus estimate of $(2.34) by 10.26 percent. This is a 41.76 percent decrease over losses of $(1.82) per share from the

Benzinga Newsdesk

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech shares fall after Q1 revenue miss and wider net loss, despite lower-than-expected loss and long-term cost-saving plans.

Vandana Singh

Earnings Scheduled For May 5, 2026

Benzinga Insights

PRO
BioNTech Affirms FY2026 Sales Guidance of $2.328B-$2.678B vs $2.560B Est

BioNTech (NASDAQ:BNTX) affirms FY2026 sales outlook from $2.328 billion-$2.678 billion to $2.328 billion-$2.678 billion vs $2.560 billion estimate.

Benzinga Newsdesk

PRO
BioNTech Q1 Adj. EPS $(2.28) Beats $(2.52) Estimate, Sales $138.000M Miss $214.620M Estimate

BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.28) per share which beat the analyst consensus estimate of $(2.52) by 9.52 percent. This is a 25.27 percent decrease over losses of $(1.82) per share from the same

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved